Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESENDO)

December 21, 2011 updated by: AstraZeneca

Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)

This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients

Study Overview

Status

Completed

Conditions

Detailed Description

MC MD

Study Type

Observational

Enrollment (Actual)

4950

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
      • Busan, Korea, Republic of
        • Research Site
      • Gwangju, Korea, Republic of
        • Research Site
      • Incheon, Korea, Republic of
        • Research Site
      • Seoul, Korea, Republic of
        • Research Site
    • Chungcheongbuk-do
      • Cheongju, Chungcheongbuk-do, Korea, Republic of
        • Research Site
    • Chungcheongnam-do
      • Cheonan, Chungcheongnam-do, Korea, Republic of
        • Research Site
      • Tae, Chungcheongnam-do, Korea, Republic of
        • Research Site
    • Gyeonggi-do
      • Anyang, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Bucheon, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Bundang, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Goyang, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Guri, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Uijeongbu, Gyeonggi-do, Korea, Republic of
        • Research Site
    • Jeollabuk-do
      • Gwangju, Jeollabuk-do, Korea, Republic of
        • Research Site
      • Iksan, Jeollabuk-do, Korea, Republic of
        • Research Site
    • Kangwon-do
      • Chuncheon, Kangwon-do, Korea, Republic of
        • Research Site
    • Kyeongsangbuk-do
      • Daegu, Kyeongsangbuk-do, Korea, Republic of
        • Research Site
      • Deagu, Kyeongsangbuk-do, Korea, Republic of
        • Research Site
    • Kyeongsangnam-do
      • Busan, Kyeongsangnam-do, Korea, Republic of
        • Research Site
      • Changwon, Kyeongsangnam-do, Korea, Republic of
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Primary Care

Description

Inclusion Criteria:

  • Patient who has a dyslipidemia with a lipid profile result within 3 months
  • Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.

Exclusion Criteria:

  • Patient who involved in this study previously.
  • Patient who participated in other clinical study with study drug within 90 days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Dyslipidemia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cholesterol goal attainment rate according to NCEP-ATP III guideline
Time Frame: Once, at enrollment
Once, at enrollment

Secondary Outcome Measures

Outcome Measure
Time Frame
Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.
Time Frame: Once, at enrollment
Once, at enrollment
Cholesterol goal attainment rate related to CHD or disease history
Time Frame: Once, at enrollment
Once, at enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Principal Investigator: Jeong Ui Park, Samsung Medical Center
  • Principal Investigator: Jong sung Kim, Seoul National University Hospital
  • Principal Investigator: Sung woo Park, Kangbuk Samsung Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Actual)

October 1, 2011

Study Completion (Actual)

October 1, 2011

Study Registration Dates

First Submitted

June 7, 2011

First Submitted That Met QC Criteria

June 13, 2011

First Posted (Estimate)

June 14, 2011

Study Record Updates

Last Update Posted (Estimate)

December 22, 2011

Last Update Submitted That Met QC Criteria

December 21, 2011

Last Verified

December 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-CKR-XXX-2011/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslipidemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe